Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Byfavo. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Remimazolam Besylate (sold as Byfavo), first approved Jul 2, 2020, with 0 new uses approved and 0 published complete response letters.
First approved: Jul 2, 2020
Applications: 1
New uses approved: 0
Complete response letters: 0
First approved in the EU: Mar 26, 2021
First approved in Japan: Jan 23, 2020
Approvals in the EU (EMA)
First approved in the EU 9 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
First approved in Japan 5 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Anerem, new approval(1) A drug with a new indication and a new dosage in an additional dosage form for sedation during gastrointestinal endoscopy. · Mundipharma K.K. · Jun 24, 2025
Anerem, new ingredientA drug with a new active ingredient indicated for the induction and maintenance of general anesthesia. · Mundipharma K.K. · Jan 23, 2020
Clinical Trials
17 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA